Suppr超能文献

一般控制非抑制性2激酶的激活可保护人肾小球内皮细胞免受有害的高糖诱导分子途径的影响。

Activation of general control nonderepressible 2 kinase protects human glomerular endothelial cells from harmful high-glucose-induced molecular pathways.

作者信息

Eleftheriadis Theodoros, Tsogka Konstantina, Pissas Georgios, Antoniadi Georgia, Liakopoulos Vassilios, Stefanidis Ioannis

机构信息

Department of Nephrology, Medical School, University of Thessaly, Neo Ktirio, Mezourlo Hill, 41110, Larissa, Greece.

出版信息

Int Urol Nephrol. 2016 Oct;48(10):1731-9. doi: 10.1007/s11255-016-1377-x. Epub 2016 Jul 27.

Abstract

PURPOSE

Considering the referred beneficial effects of protein restriction on diabetic nephropathy (DN) and the role of renal endothelium in its pathogenesis, we evaluated the effect of general control nonderepressible 2 (GCN2) kinase activation, a sensor of amino acid deprivation, on known detrimental molecular pathways in primary human glomerular endothelial cells (GEnC).

METHODS

GEnC were cultured under normal or high-glucose conditions in the presence or not of the GCN2 kinase activator, tryptophanol. Glucose transporter 1 (GLUT1) expression was assessed by western blotting and reactive oxygen species (ROS) using a fluorogenic probe. Activities of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and protein kinase C (PKC) were assessed by commercial activity assays, sorbitol colorimetrically, methylglyoxal by ELISA and O-linked β-N-acetyl glucosamine (O-GlcNAc)-modified proteins by western blotting.

RESULTS

High glucose induced GLUT1 expression, increased ROS and inhibited GAPDH. Also it increased the polyol pathway product sorbitol, PKC activity, the level of the O-GlcNAc-modified proteins that produced by the hexosamine pathway and the advanced glycation endproducts' precursor methylglyoxal. Co-treatment of GEnC with tryptophanol restored the above high-glucose-induced alterations.

CONCLUSIONS

Activation of GCN2 kinase protects GEnC from high-glucose-induced harmful molecular pathways. By inhibiting concurrently many pathways involved in DN pathogenesis, GCN2 kinase may serve as a pharmaceutical target for the treatment of DN.

摘要

目的

鉴于蛋白质限制对糖尿病肾病(DN)具有有益作用,且肾内皮细胞在其发病机制中发挥作用,我们评估了一般控制非抑制性2(GCN2)激酶激活(一种氨基酸剥夺传感器)对原代人肾小球内皮细胞(GEnC)中已知有害分子途径的影响。

方法

在存在或不存在GCN2激酶激活剂色氨醇的情况下,将GEnC在正常或高糖条件下培养。通过蛋白质印迹法评估葡萄糖转运蛋白1(GLUT1)的表达,并使用荧光探针评估活性氧(ROS)。通过商业活性测定法评估甘油醛3-磷酸脱氢酶(GAPDH)和蛋白激酶C(PKC)的活性,比色法测定山梨醇,酶联免疫吸附测定法测定甲基乙二醛,蛋白质印迹法测定O-连接的β-N-乙酰葡糖胺(O-GlcNAc)修饰的蛋白质。

结果

高糖诱导GLUT1表达,增加ROS并抑制GAPDH。此外,它还增加了多元醇途径产物山梨醇、PKC活性、己糖胺途径产生的O-GlcNAc修饰蛋白水平以及晚期糖基化终产物的前体甲基乙二醛。色氨醇与GEnC共同处理可恢复上述高糖诱导的改变。

结论

GCN2激酶的激活可保护GEnC免受高糖诱导的有害分子途径的影响。通过同时抑制许多参与DN发病机制的途径,GCN2激酶可能成为治疗DN的药物靶点。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验